# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immuno...
Truist Securities analyst Gregory Fraser maintains Beyond Air (NASDAQ:XAIR) with a Buy and lowers the price target from $10 ...
"In the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the s...
Beyond Air (NASDAQ:XAIR) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.53) by...